



RNA Interference: A Promising Approach for the Treatment of Viral Hepatitis

Mahsa Motavaf^{1,2}, Seyed Moayed Alavian^{1,2*}

¹ Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
² Tehran Hepatitis Center, Tehran, IR Iran

ARTICLE INFO

Article type:
Editorial

Article history:
Received: 26 Dec 2011
Revised: 29 Dec 2011
Accepted: 09 Jan 2012

Keywords:
RNA
Viral, Hepatitis, Human
Therapeutic

► **Implication for health policy/practice/research/medical education:**

RNA interference (RNAi), the degradation of cognate mRNA by small interfering RNA (siRNA), has emerged as a novel therapeutic entity for viral infections. This novel strategy may offer the potential to eliminate HCV infection. This article is useful for all researchers who concern about new therapeutic approaches for viral hepatitis.

► **Please cite this paper as:**

Motavaf M, Alavian SM. RNA Interference: A Promising Approach for the Treatment of Viral Hepatitis. *Hepat Mon.* 2012; 7-8. DOI: 10.5812/kowsar.1735143X.812

Copyright © 2012 Kowsar M. P. Co. All rights reserved.

Hepatitis viruses are the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The hepatitis C virus (HCV), together with the hepatitis B virus (HBV), accounts for 75% of all cases of liver disease around the world, with chronic hepatitis, cirrhosis, and HCC causing 500,000 to 1.2 million deaths per year (1-3). More than 170 million people worldwide have chronic HCV infection. According to the 2002 WHO report, chronic liver diseases were responsible for 1.4 million deaths, including 796,000 deaths due to cirrhosis and 616,000 deaths due to primary liver cancer. At least 20% of these deaths (more than 280,000 deaths) are probably attributable to HCV infection (4). With the WHO officially recognizing hepatitis as a global health issue, more research needs to be conducted to develop new therapeutic interventions. Current antiviral therapies for chronic viral hepatitis are effective only in approximately half of the patients (5). The most widely available agents for the treatment of chronic hepatitis are interferon- α (IFN- α) and nucleoside analogs such as lamivudine or adefovir (6, 7). However, treatment with these agents has some disadvantages,

including possible serious adverse effects in the case of interferon treatment or recurrence of viremia after discontinuation of therapy and development of resistant mutants after prolonged lamivudine treatment (8-11). Moreover, nucleoside analogs such as 3TC-lamivudine only interfere with viral replication and do not induce cessation of the process. The low efficacy of these agents, their adverse effects, and development of resistant viral mutations are major impediments to the clinical application of these agents for the treatment of viral hepatitis (6). These shortcomings necessitate the development of alternative treatment strategies. Sequence-specific gene silencing using RNA interference (RNAi) is a Nobel prize-winning technology that represents a promising new approach to overcome viral infections (5, 12-14). RNA interference is an evolutionary mechanism for protecting the genome against invasion by mobile genetic elements such as transposons and viruses (6). It is a process by which small interfering RNA (siRNA) with specific target sequences induce silencing of homologous genes by binding to their complementary mRNA and inducing the elimination of the mRNA molecule (15). This process occurs post-transcriptionally in the cytoplasm and is mediated by small RNA molecules (21 to 25 nucleotides in length) that bind to their complementary mRNA targets and silence the expression of these targets (6). The phenomenon of RNA interference (RNAi) was first de-

* Corresponding author: Seyed Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2188945186, Fax: +98-2188945188, E-mail: alavian@thc.ir

scribed by Fire *et al.* They observed that in the nematode *Caenorhabditis elegans*, the presence of double-stranded RNA (dsRNA) resulted in sequence-specific gene silencing at the post-transcriptional level. The RNAi pathway has since been recognized as a conserved biological pathway, and several experimental models have contributed to the understanding of this process (15, 16).

Subsequent to the discovery of RNAi pathways and their ability to silence a specific gene sequence, researchers have proposed that this natural protection response might be used for therapeutic purposes. The ability to achieve potent knockdown of a gene of interest with high sequence specificity makes RNAi a powerful tool for treating a variety of diseases. Since RNAi, as a natural mechanism of defense, has an antiviral effect in plants and mammalian cells, pathogenic human viruses were considered a good starting point for evaluating the therapeutic potential of RNAi (17-20). Recently, several reports have demonstrated the use of RNAi for weakening of viral infection and replication in cultured cells. For instance, several studies have shown its antiviral effects against HIV and HBV and HCV (6, 12, 21-25).

The *in vivo* efficacy of RNAi against a virus was first demonstrated by McCaffrey *et al.* In their study, they co-delivered an HBV replicon and an expression unit encoding an anti-HBV RNAi in mice. Their results showed that a significant knockdown (99%) of the HBV core antigen in hepatocytes could be achieved by the RNAi mechanism, providing an important proof of principle for future antiviral applications of RNAi in the liver.(12) In another study designed by Amir Shlomai and Yosef Shaul, in order to evaluate the anti-HBV therapeutic potential of RNAi, the levels of viral proteins and transcripts as well as the viral replicative forms were analyzed. The results showed that RNAi is an efficient approach for reducing the level of HBV transcripts and proteins and for suppressing HBV replication (26). Many other studies have shown that co-transfection of RNAi molecules targeting specific sequences in the HBV or HCV genome results in a significant reduction in the corresponding levels of viral transcripts and proteins. This reduction is highly selective, because only the homologous transcripts and proteins were eliminated (8, 13). Thus, RNAi-based therapies have a number of inherent and fundamental benefits (8, 27).

Authors' Contribution

None declared.

Financial Disclosure

None declared.

References

- Mahboobi N, Agha-Hosseini F, Safari S, Lavanchy D, Alavian SM. Hepatitis B virus infection in dentistry: a forgotten topic. *J Viral Hepat.* 2010;**17**(5):307-16.
- Henry SD, van der Wegen P, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. *Mol Ther.* 2006;**14**(4):485-93.
- Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. *Hepat Mon.* 2008;**8**(4):281-94.
- Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. *Hepat Mon.* 2009;**9**(2):95-102.
- Pan Q, Henry SD, Metselaar HJ, Scholte B, Kwekkeboom J, Tilanus HW, et al. Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. *J Mol med.* 2009;**87**(7):713-22.
- Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. *Pharm Res.* 2008;**25**(1):72-86.
- Pramoolsinsup C. Management of viral hepatitis B. *J Gastroenterol Hepatol.* 2002;**17**(Suppl):S125-45.
- Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. *Hepatology.* 2003;**37**(4):764-70.
- Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. *Antivir Chem Chemother.* 2001;**12**(1):1-35.
- Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. *Clin Infect Dis.* 2003;**36**(6):687-96.
- Chasseguet-Smirgel J. Sadomasochism in the perversions: some thoughts on the destruction of reality. *J Am Psychoanal Assoc.* 1991;**39**(2):399-415.
- McCaffrey AP. RNA interference inhibitors of hepatitis B virus. *Ann NY Acad Sci.* 2009;**1175**:15-23.
- Wilson JA, Jayasena S, Khvorova A, Sabatino S, Rodrigue-Gervais IG, Arya S, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. *P Natl Acad Sci USA.* 2003;**100**(5):2783-8.
- Mahanthappa N. Translating RNA interference into therapies for human disease. *Pharmacogenomics.* 2005;**6**(8):879-83.
- Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature.* 1998;**391**(6669):806-11.
- Silva JM, Hammond SM, Hannon GJ. RNA interference: a promising approach to antiviral therapy? *Trends Mol Med.* 2002;**8**(11):505-8.
- Aravin A, Tuschl T. Identification and characterization of small RNAs involved in RNA silencing. *FEBS letters.* 2005;**579**(26):5830-40.
- Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.* 2001;**15**(2):188-200.
- Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods.* 2002;**26**(2):199-213.
- Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. *Science.* 1999;**286**(5441):950.
- Zhang YL, Cheng T, Cai YJ, Yuan Q, Liu C, Zhang T, et al. RNA Interference inhibits hepatitis B virus of different genotypes *in vitro* and *in vivo*. *BMC Microbiol.* 2010;**10**:214.
- Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat Med.* 2003;**9**(3):347-51.
- Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. *P Natl Acad Sci USA.* 2003;**100**(13):7797-802.
- Sun D, Rosler C, Kidd-Ljunggren K, Nassal M. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. *J Hepatol.* 2010;**52**(6):817-26.
- Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. *Science.* 2005;**309**(5740):1519-24.
- Wright TL. Introduction to chronic hepatitis B infection. *Am J Gastroenterology.* 2006;**101**(1):1.
- Manoharan M. RNA interference and chemically modified siRNAs. *Nucleic Acids Res Suppl.* 2003;**3**:115-6.